Healthcare distribution agreements amended after Solventum divestiture

Strategic Transactions View source PDF Explain this filing

3MINDIA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹29100.00

prior close

₹29225.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-2.8% vs market

Diversified peers, median of 13sector-0.1%-1.0% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Diversified peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.9

15m

+1.5

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+1.7-2.8-0.1-1.0

Next day

-0.9pendingpending+1.0-1.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Diversified peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

3M India approved changes to March 2024 healthcare agreements with Solventum. Products sold by Solventum to Thermo Fisher will be removed from distribution once conditions are met. Other products get a two-year extension, making the distribution term seven years from March 2024. 3M India will receive a one-time US$13 million payment from Thermo Fisher. Future Solventum divestitures earn 100% of prior-year net sales to March 2029, then 60% to March 2031.

Likely market impact

Secures US$13 million and extends the distribution term, but narrows the product range 3M India can supply.